Printer Friendly

NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1992 RESULTS

 MIAMI, March 1, 1993 /PRNewswire/ -- North American Biologicals, Inc. ("NABI") (NASDAQ: NBIO) today announced fiscal year 1992 results.
 For the year ended Dec. 31, 1992, the company reported net sales of $82.4 million, with a net loss $573,000, or 4 cents per share, compared to sales of $68.2 million and net earnings of $2.2 million or 14 cents per share for the prior year.
 NABI management noted that in the fourth quarter, the company achieved operating income of $326,000, as compared with a third quarter operating loss of $620,000, partially as a result of the profit contribution from H-BIG(R), NABI's first immune globulin therapeutic product, as well as from reduced operating costs. NABI's 1992 operating results reflect increased costs associated with collecting plasma in response to an industry-wide plasma shortage, and a substantial increase in interest and amortization expense, largely associated with NABI's repurchase of 42 percent of its outstanding shares from its majority shareholder, Continental Pharma Cryosan, Inc., completed in March 1992.
 "Our 1992 performance reflects NABI's transition from being solely a raw materials supplier to developing, manufacturing and marketing plasma-based pharmaceutical products," said David J. Gury, NABI's chairman, president and chief executive officer. "NABI now has the opportunity to gain from its independence by pursuing higher-margin products, such as H-BIG, which is already generating annualized sales of more than $5 million," he said.
 "For 1993, we are optimistic that the combination of continued strong plasma demand, improved product pricing, and increased plasma collections leading to cost efficiencies, as well as the contribution from higher-margin products such as H-BIG, will return NABI to profitability," Gury added.
 North American Biologicals, Inc. is the world's largest independent provider of human blood plasma elements to the health care industry, and is dedicated to improving the quality of human life by providing plasma and plasma-based products for diagnosis or therapy of immune disorders.
 NORTH AMERICAN BIOLOGICALS, INC.
 SELECTED CONSOLIDATED FINANCIAL DATA
 ($ thousands, except per share amounts)
 For the Years Ended
 December 31
 1992 1991
 Net Sales $ 82,355 $ 68,230
 Cost of Products sold 71,497 59,041
 Gross Margin 10,858 9,189
 Selling, general and administrative
 expenses 6,550 5,303
 Other operating expenses 2,448 602
 Operating income 1,860 3,284
 Interest and other income 42 342
 Interest expense (2,470) (573)
 Income (loss) before provision for
 income taxes (568) 3,053
 Provision for income taxes (5) (836)
 Net income (loss) $ (573) $ 2,217
 Net income (loss) per share $ (0.04) $ 0.14
 Weighted average number of shares
 and common share equivalents 13,328 15,980
 -0- 3/1/93
 /CONTACT: David J. Gury, chairman, president and CEO, Alfred J. Fernandez, vice president, finance, both of North American Biologicals, Inc., 305-628-0080; Marcia A. Kean or Lori E. Martin of Feinstein Partners Inc., 617-577-8110/
 (NBIO)


CO: North American Biologicals, Inc. ST: Florida IN: MTC SU: ERN

TM -- NE010 -- 1556 03/01/93 15:49 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:492
Previous Article:UNIVERSAL INTERNATIONAL ANNOUNCES RESULTS, NEW PRESIDENT AND SALES
Next Article:SPINNAKER SECURES ADDITIONAL FINANCING
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS SECOND QUARTER 1992 RESULTS; SALES AND OPERATING INCOME AT RECORD LEVELS FOR QUARTER AND YEAR TO DATE
NORTH AMERICAN BIOLOGICALS, INC. ANNOUNCES THIRD QUARTER AND YEAR-END 1992 OUTLOOK
GAMMA BIOLOGICALS REPORTS EARNINGS FOR SECOND QUARTER AND SIX MONTHS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS FIRST QUARTER 1993 RESULTS; RETURNS TO PROFITABILITY
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD REVENUES AND PROFITS FOR 1993
NORTH AMERICAN VACCINE, INC. ANNOUNCES OPERATING RESULTS FOR 1993
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR FIRST QUARTER 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR THIRD QUARTER AND NINE MONTHS 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD PERFORMANCE FOR 1994

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters